Switch theme
Sign up to access all valuation multiples
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.
1999
37
LTM Revenue $13.2M
LTM EBITDA $5.3M
$122M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genovis has a last 12-month revenue of $13.2M and a last 12-month EBITDA of $5.3M.
In the most recent fiscal year, Genovis achieved revenue of $12.9M and an EBITDA of $5.6M.
Genovis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genovis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $15.7M | $12.9M | XXX | XXX | XXX |
| Gross Profit | $8.7M | $14.2M | XXX | XXX | XXX |
| Gross Margin | 55% | 110% | XXX | XXX | XXX |
| EBITDA | $6.6M | $5.6M | XXX | XXX | XXX |
| EBITDA Margin | 42% | 43% | XXX | XXX | XXX |
| Net Profit | $1.1M | $6.1M | XXX | XXX | XXX |
| Net Margin | 7% | 47% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Genovis's stock price is SEK 19 (or $2).
Genovis has current market cap of SEK 1.3B (or $126M), and EV of SEK 1.2B (or $122M).
See Genovis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $122M | $126M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Genovis has market cap of $126M and EV of $122M.
Genovis's trades at 9.3x LTM EV/Revenue multiple, and 22.9x LTM EBITDA.
Analysts estimate Genovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genovis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $122M | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | XXX | XXX |
| P/E | 38.6x | XXX | XXX | XXX |
| P/E/Growth | 2.5x | XXX | XXX | XXX |
| EV/FCF | 33.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenovis's NTM/LTM revenue growth is 12%
Genovis's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Genovis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genovis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genovis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genovis acquired XXX companies to date.
Last acquisition by Genovis was XXXXXXXX, XXXXX XXXXX XXXXXX . Genovis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genovis founded? | Genovis was founded in 1999. |
| Where is Genovis headquartered? | Genovis is headquartered in Sweden. |
| How many employees does Genovis have? | As of today, Genovis has 37 employees. |
| Who is the CEO of Genovis? | Genovis's CEO is Mr. Fredrik Olsson. |
| Is Genovis publicy listed? | Yes, Genovis is a public company listed on STO. |
| What is the stock symbol of Genovis? | Genovis trades under GENO ticker. |
| When did Genovis go public? | Genovis went public in 2005. |
| Who are competitors of Genovis? | Similar companies to Genovis include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Genovis? | Genovis's current market cap is $126M |
| What is the current revenue of Genovis? | Genovis's last 12-month revenue is $13.2M. |
| What is the current EBITDA of Genovis? | Genovis's last 12-month EBITDA is $5.3M. |
| What is the current EV/Revenue multiple of Genovis? | Current revenue multiple of Genovis is 9.3x. |
| What is the current EV/EBITDA multiple of Genovis? | Current EBITDA multiple of Genovis is 22.9x. |
| What is the current revenue growth of Genovis? | Genovis revenue growth between 2023 and 2024 was -18%. |
| Is Genovis profitable? | Yes, Genovis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
